FacebookTwitterGoogle+RedditEmail

Time to Put Lives Over Patents

by Russell Mokhiber And Robert Weissman

Drug prices in the United States are out of control, and rising.

The reason is that the United States permits pharmaceuticals to be marketed by unregulated monopolies: Patent protection gives the drug companies monopoly control over their products. These companies face neither direct competition, nor price controls.

But what is the reason for the government grant of these patent monopolies (which often extend long beyond the official 20 years, thanks to a variety of Big Pharma “evergreening” tactics to block or delay the introduction of generic competition)?

Leaving aside the raw political power of the pharmaceutical industry and its allies, the policy rationale for patent monopolies is the cost of drug development. According to the drug companies, the cost of researching and developing a new drug is $800 million.

The myth of astronomical drug development costs is the figleaf behind which Big Pharma and its paid associates (inside and outside of government) hide to escape criticism for price gouging. If this myth were peeled away, Big Pharma would stand exposed. And the prospect of a more rational system of drug development and pricing would rise dramatically.

This matter could be resolved, simply, if the drug companies were to open their books and reveal their actual investments in R&D. Instead, they implausibly claim that this information would give away trade secrets and must remain proprietary.

The industry claim of $800 million costs per drug relies on a study from an industry-funded research center at Tufts University in Boston. Tufts researchers supposedly had access to industry data to come up with their figure, but no one else is able to see the underlying data. So if you choose to believe in this number, it is simply a matter of faith.

To get closer to the actual figures for the cost of drug development and company per drug expenditures on R&D, you have to peel away the assumptions and built-in biases of the Tufts-industry study.

Approximately half of the Tufts-industry estimates are attributed to financing costs, known as opportunity cost of capital. Money invested in drug R&D could have been invested in treasury bonds, say. While the bonds would start returning revenues right away, R&D returns are not realized for years, until a drug is discovered, developed, approved and put on the market. So in the Tufts-industry study, a “cost” of development is the forsworn income during the period of development.

This is all true, as far it goes, but it is not how people normally think about “cost.” As James Love of the Consumer Project on Technology says, it is the equivalent of saying the cost of a car is not the sticker price, but the sticker price plus interest payments on a car loan.

Exacerbating the problem, the researchers may pick an unreasonably high interest rate. They may also set the period for drug development as too long — in the Tufts-industry model, relatively small delays in getting the drug to market lead to big increases in the overall cost.

The Tufts-industry estimate is for the cost of new chemical entities for which the industry was wholly responsible — that is, where there was no substantial public contribution to R&D.

It turns out, however, that the vast majority of new drugs Big Pharma brings to market do not involve new chemical compounds. A May 2002 study by the National Institute for Health Care Management (NIHCM) Foundation found that two-thirds of the prescription drugs approved by the FDA between 1989 and 2000 were modified versions of existing medicines or identical to drugs already on the market (and only about 15 percent were both new and deemed by the FDA to provide significant improvement over existing medicines). Pharma denies it, but there is every reason to believe these less novel products are far cheaper to bring to market.

Then there’s the not insignificant fact that the case of drugs brought to market without government support is the exception, not the norm. The federal government supports an enormous amount of research, and funds the earliest and riskiest portions of the R&D process: basic research and the earlier phases of clinical trials.

Finally, the Tufts-industry figures seem to wildly inflate the cost of clinical testing. Looking at company filings with the IRS for tax credits on research for “orphan drugs” (drugs which treat small populations), however, the Consumer Project on Technology found that — adjusted for risk — drug companies report expenditures of only $7.9 million on clinical trials, less than 1 percent of the overall estimate.

Even if the costs for this category of drug are below average, as the industry claims — even if they were, implausibly, a tenth of the average — this would still suggest a much lower total development cost than the Tufts-industry estimate.

Any honest examination of available evidence on the costs of drug development suggests the United States — and most of the rest of the world, which thanks to the <U.S./industry> strong-arming tactics in international trade negotiations, now maintains or soon will adopt <U.S.-style> patent rules — is massively overcompensating Big Pharma for its work in bringing drugs to market.

With the U.S. healthcare system bursting at the seams, seniors draining their bank accounts to buy drugs, and millions of people around the world going without medicines, the time has come for fundamental reform.

Meaningful reform might include ending the industry’s patent extension tricks, licensing drugs developed with public monies on a nonexclusive basis to permit price-reducing competition (or at least permitting competition where prices are excessive), and considering rollbacks to the 20-year patent term and the adoption of price controls.

But even these measures may inadequate. Why couldn’t the government simply take over the job of drug development, and then let private companies manufacture and distribute medicines in a competitive environment — doing away with patent monopolies on drugs altogether?

Russell Mokhiber is editor of the Washington, D.C.-based Corporate Crime Reporter. Robert Weissman is editor of the Washington, D.C.-based Multinational Monitor, and co-director of Essential Action. They are co-authors of Corporate Predators: The Hunt for MegaProfits and the Attack on Democracy (Monroe, Maine: Common Courage Press, 1999.

(c) Russell Mokhiber and Robert Weissman

 

May 04, 2016
Kshama Sawant
It’s Not About Bernie: Why We Can’t Let Our Revolution Die in Philadelphia
Conn Hallinan
Baiting the Bear: Russia and NATO
Joshua Frank
Hanford’s Leaky Nuke Tanks and Sick Workers, A Never-Ending Saga
Paul Craig Roberts
TIPP: Advancing American Imperialism
Ted Rall
Hillary to Bernie Supporters: Don’t Vote for Me!
Eric Draitser
Hillary Clinton and Wall Street’s Neoliberal War on Latin America
Leslie Scott
The Story of Jill Stein: Putting People, Peace and the Planet Before Profits
Ann Garrison
Building the Greens Into a Mass Party: Interview with Bruce Dixon
Tom Clifford
Crying Rape: Trump’s Slurs Against China
Lawrence Davidson
Getting Rid of Bad Examples: Andrew Jackson & Woodrow Wilson
Ellen Brown
Bank of North Dakota Soars Despite Oil Bust: A Blueprint for California?
Nelson Valdes
Is Fidel Castro Outside or Part of Mainstream Thinking? A Selection of Quotes
Jesse Jackson
Don’t Send Flint Down the Drain: Fix It!
Nathan Riley
Help Bernie Keep His Halo
Rivera Sun
Remembering Nonviolent History: Freedom Rides
Clancy Sigal
Rachel and the Isolationists: How Maddow Blew It
Laura Finley
Changing the Conversation About “The Woman Card”
CJ Hopkins
Coming this Summer … Revenge of the Bride of Sophie’s Choice
May 03, 2016
Gary Leupp
Hillary Clinton’s Foreign Policy Resumé: What the Record Shows
Michèle Brand – Arun Gupta
What is the “Nuit Debout”?
Chuck Churchill
The Failures of Capitalism, Donald Trump and Right Wing Terror
Dave Marsh
Bernie and the Greens
John Wight
Zionism Should be on Trial, Not Ken Livingstone
Rev. John Dear
A Dweller in Peace: the Life and Times of Daniel Berrigan
Patrick Cockburn
Saudi Arabia’s Great Leap Forward: What Would Mao Think?
Doug Johnson Hatlem
Electoral Votes Matter: Hillary Clinton or Bernie Sanders vs Donald Trump
Chris Gilbert
Venezuela Today: This Must Be Progress
Pepe Escobar
The Calm Before the Coming Global Storm
Ruth Fowler
Intersecting with the Identity Police (Or Why I Stopped Writing Op-Eds)
Victor Lasa
The Battle Rages on in Spain: the Country Prepares for Repeat Elections in June
Jack Rasmus
Is the US Economy Heading for Recession?
Dean Baker
Time for an Accountable Federal Reserve
Ted Rall
Working for US Gov Means Never Saying Sorry
Dave Welsh
Hunger Strikers at Mission Police Station: “Stop the execution of our people”
John Eskow
The Death of Prince and the Death of Lonnie Mack
May 02, 2016
Michael Hudson – Gordon Long
Wall Street Has Taken Over the Economy and is Draining It
Paul Street
The Bernie Fade Begins
Ron Jacobs
On the Frontlines of Peace: the Life of Daniel Berrigan
Louis Yako
Dubai Transit
Bill Quigley
Teacher, Union Leader, Labor Lawyer: Profile of Chris Williams Social Justice Advocate
Patrick Cockburn
Into the Green Zone: Iraq’s Disintegrating Political System
Lawrence Ware
Trump is the Presidential Candidate the Republicans Deserve
Ron Forthofer
Just Say No to Corporate Rule
Ralph Nader
The Long-Distance Rebound of Bernie Sanders
Ken Butigan
Remembering Daniel Berrigan, with Gratitude
FacebookTwitterGoogle+RedditEmail